Literature DB >> 16213464

Novel time-dependent vascular actions of Delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma.

Saoirse E O'Sullivan1, Elizabeth J Tarling, Andrew J Bennett, David A Kendall, Michael D Randall.   

Abstract

Cannabinoids have widespread effects on the cardiovascular system, only some of which are mediated via G-protein-coupled cell surface receptors. The active ingredient of cannabis, Delta9-tetrahydrocannabinol (THC), causes acute vasorelaxation in various arteries. Here we show for the first time that THC also causes slowly developing vasorelaxation through activation of peroxisome proliferator-activated receptors gamma (PPARgamma). In vitro, THC (10 microM) caused time-dependent vasorelaxation of rat isolated arteries. Time-dependent vasorelaxation to THC was similar to that produced by the PPARgamma agonist rosiglitazone and was inhibited by the PPARgamma antagonist GW9662 (1 microM), but not the cannabinoid CB1 receptor antagonist AM251 (1 microM). Time-dependent vasorelaxation to THC requires an intact endothelium, nitric oxide, production of hydrogen peroxide, and de novo protein synthesis. In transactivation assays in cultured HEK293 cells, THC-activated PPARgamma, transiently expressed in combination with retinoid X receptor alpha and a luciferase reporter gene, in a concentration-dependent manner (100 nM-10 microM). In vitro incubation with THC (1 or 10 microM, 8 days) stimulated adipocyte differentiation in cultured 3T3L1 cells, a well-accepted property of PPARgamma ligands. The present results provide strong evidence that THC is a PPARgamma ligand, stimulation of which causes time-dependent vasorelaxation, implying some of the pleiotropic effects of cannabis may be mediated by nuclear receptors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213464     DOI: 10.1016/j.bbrc.2005.09.121

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  53 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Tempo and mode in the endocannaboinoid system.

Authors:  John M McPartland; Ryan W Norris; C William Kilpatrick
Journal:  J Mol Evol       Date:  2007-08-04       Impact factor: 2.395

3.  Mitochondrial biogenesis is altered in HIV+ brains exposed to ART: Implications for therapeutic targeting of astroglia.

Authors:  Mary K Swinton; Aliyah Carson; Francesca Telese; Ana B Sanchez; Benchawanna Soontornniyomkij; Leila Rad; Isabella Batki; Brandi Quintanilla; Josué Pérez-Santiago; Cristian L Achim; Scott Letendre; Ronald J Ellis; Igor Grant; Anne N Murphy; Jerel Adam Fields
Journal:  Neurobiol Dis       Date:  2019-06-22       Impact factor: 5.996

4.  A shifted repertoire of endocannabinoid genes in the zebrafish (Danio rerio).

Authors:  J M McPartland; Michelle Glass; Isabel Matias; Ryan W Norris; C William Kilpatrick
Journal:  Mol Genet Genomics       Date:  2007-01-26       Impact factor: 3.291

5.  'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors.

Authors:  W-S V Ho; D A Barrett; M D Randall
Journal:  Br J Pharmacol       Date:  2008-08-11       Impact factor: 8.739

6.  Cannabichromene is a cannabinoid CB2 receptor agonist.

Authors:  Michael Udoh; Marina Santiago; Steven Devenish; Iain S McGregor; Mark Connor
Journal:  Br J Pharmacol       Date:  2019-11-21       Impact factor: 8.739

7.  Neuromolecular Mechanisms of Cannabis Action.

Authors:  Yousra Adel; Stephen P H Alexander
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis.

Authors:  Aitor G Granja; Francisco Carrillo-Salinas; Alberto Pagani; María Gómez-Cañas; Roberto Negri; Carmen Navarrete; Miriam Mecha; Leyre Mestre; Bend L Fiebich; Irene Cantarero; Marco A Calzado; Maria L Bellido; Javier Fernandez-Ruiz; Giovanni Appendino; Carmen Guaza; Eduardo Muñoz
Journal:  J Neuroimmune Pharmacol       Date:  2012-09-14       Impact factor: 4.147

Review 9.  The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

Authors:  R G Pertwee
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 10.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.